This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Erythromycin

Read time: 1 mins
Marketing start date: 26 Nov 2024
...
 

Summary of product characteristics


Effective Time

20231006

Version

1

Spl Product Data Elements

Erythromycin Erythromycin ERYTHROMYCIN ERYTHROMYCIN ALUMINUM OXIDE CROSCARMELLOSE SODIUM CROSPOVIDONE (120 .MU.M) D&C RED NO. 30 FERRIC OXIDE RED FERRIC OXIDE YELLOW HYDROXYPROPYL CELLULOSE (90000 WAMW) HYPROMELLOSE 2910 (6 MPA.S) HYPROMELLOSE PHTHALATE (31% PHTHALATE, 40 CST) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE 101 MICROCRYSTALLINE CELLULOSE 102 POLYETHYLENE GLYCOL 6000 POVIDONE K30 POVIDONE K90 PROPYLENE GLYCOL SILICON DIOXIDE SODIUM HYDROXIDE SORBIC ACID SORBITAN MONOOLEATE TALC TITANIUM DIOXIDE TRISODIUM CITRATE DIHYDRATE peach to pink 1755 Erythromycin Erythromycin ERYTHROMYCIN ERYTHROMYCIN ALUMINUM OXIDE CROSCARMELLOSE SODIUM CROSPOVIDONE (120 .MU.M) D&C RED NO. 30 FERRIC OXIDE RED HYDROXYPROPYL CELLULOSE (90000 WAMW) HYPROMELLOSE 2910 (6 MPA.S) HYPROMELLOSE PHTHALATE (31% PHTHALATE, 40 CST) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE 101 MICROCRYSTALLINE CELLULOSE 102 POLYETHYLENE GLYCOL 6000 POVIDONE K30 POVIDONE K90 PROPYLENE GLYCOL SILICON DIOXIDE SODIUM HYDROXIDE SORBIC ACID SORBITAN MONOOLEATE TALC TITANIUM DIOXIDE TRISODIUM CITRATE DIHYDRATE light pink to pink 1756

Application Number

ANDA215440

Brand Name

Erythromycin

Generic Name

Erythromycin

Product Ndc

70771-1732

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1732-3 in bottle of 30 tablets Erythromycin Tablets USP, 250 mg Rx only 30 tablets NDC 70771-1733-3 in bottle of 30 tablets Erythromycin Tablets USP, 500 mg Rx only 30 tablets 250 mg 500 mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.